Kind of chemokine/biomolecule | Target | Results | References |
---|---|---|---|
CXCL12 | AML cells | Dampening effect on MSC-mediated resistance to FLT3 inhibition | [95] |
CXCL12 | CML cells | ↓Imatinib-induced cell death | [76] |
CXCL12 | LSCs of CML | Maintain quiescent of LSCs and TKI-resistant | [83] |
Periostin | B-ALL cells | ↑B-ALL cell-derived CCL2, ↑ leukemia burden | [88] |
Lumican | LSCs of Nalm-6 cell line | Downregulation of anti-apoptotic, resistance to chemotherapy | [89] |
CCL3, CCL4, matrix metalloproteinases (MMP)-13, IL-1, IL-3, IL-6, and IL-17 | MM cells | Differentiation to osteoclast, bone destruction in MM | [72] |
VCAM-1, SDF1, Wnt | AML cells | Residual disease maintenance, drug resistance and disease relapse | |
Axl | AML cells | Prognostic factor and therapeutic target | [87] |
SDF-1α/CXCR4 | CLL cells | Intercellular trafficking of CLL cells | [94] |
CXCR4/CXCL12 | CML cells | ↓Caspase-3 activation, Bcl-XL expression modulation after treatment with imatinib | [93] |